Radiation With Immunotherapy May Be a Double-Edged Sword-How Can We Learn From Recent Negative Clinical Trials?

JAMA Oncol. 2024 Aug 1;10(8):1019-1020. doi: 10.1001/jamaoncol.2024.1527.

Authors

Heather M McGee^{1

2}, Terence M Williams^{1

3}, Percy Lee⁴

Affiliations

¹ Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
² Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California.
³ Department of Cancer Genetics & Epigenetics, Beckman Research Institute of City of Hope, Duarte, California.
⁴ Department of Radiation Oncology, City of Hope Orange County, Irvine, California.

PMID: 38842841
DOI: 10.1001/jamaoncol.2024.1527

No abstract available

Plain language summary

This Viewpoint explains differences between recent studies using radiotherapy with immunotherapy and possible reasons for their different outcomes.

MeSH terms

Clinical Trials as Topic*
Combined Modality Therapy
Humans
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy* / adverse effects
Immunotherapy* / methods
Neoplasms* / immunology
Neoplasms* / radiotherapy
Neoplasms* / therapy

Substances

Immune Checkpoint Inhibitors